Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer Inc. Chairman and CEO Albert Bourla acquired 23 phantom stock units on December 15, 2025, through a deferred compensation plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 23 phantom stock units.
• The transaction occurred on December 15, 2025.
• Each unit represents one phantom share of common stock.
• The acquisition price per unit was $26.43.
• Following this transaction, Bourla beneficially owns 742,986 phantom stock units directly.
• These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The units are settled in cash upon separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 6

Explanation: The acquisition of phantom stock units by the CEO is generally a neutral to slightly positive signal, indicating continued executive alignment with the company's performance, though it's part of a deferred compensation plan rather than an open market purchase.

Positives

• Acquisition of phantom stock units by the Chairman and CEO indicates continued alignment of management's interests with shareholder value.
• Participation in the Nonfunded Deferred Compensation and Supplemental Savings Plan suggests a long-term commitment to the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, as it is a report of a past transaction.

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for public company executives. It does not provide broader industry context or competitive analysis.

Related Party Transactions

• Acquisition of 23 phantom stock units by Chairman & CEO Albert Bourla through the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Stakeholder Impact

• Shareholders: The transaction shows continued executive ownership and participation in long-term incentive plans, which can be viewed positively as aligning management interests with shareholder value.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by Pfizer's Chairman and CEO, Albert Bourla, as part of a deferred compensation plan. While it indicates continued executive alignment, the transaction size (23 units) and nature (not an open market purchase) are not significant enough to warrant a change in investment recommendation based solely on this filing. It is a standard disclosure of executive compensation activity.

Keywords

Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, Executive Compensation